{"organizations": [], "uuid": "ee6477bbfe9098aa3b098b01bb7a1becab3856c9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180507.html", "section_title": "Archive News &amp; Video for Monday, 07 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-immune-pharmaceuticals-says-board/brief-immune-pharmaceuticals-says-board-will-not-pursue-spin-off-of-cytovia-unit-idUSASC0A02Y", "country": "US", "domain_rank": 408, "title": "Immune Pharmaceuticals Says Board Will Not Pursue Spin-Off Of Cytovia Unit", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-07T20:40:00.000+03:00", "replies_count": 0, "uuid": "ee6477bbfe9098aa3b098b01bb7a1becab3856c9"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-immune-pharmaceuticals-says-board/brief-immune-pharmaceuticals-says-board-will-not-pursue-spin-off-of-cytovia-unit-idUSASC0A02Y", "ord_in_thread": 0, "title": "Immune Pharmaceuticals Says Board Will Not Pursue Spin-Off Of Cytovia Unit", "locations": [], "entities": {"persons": [{"name": "daniel teper", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "immune pharmaceuticals inc", "sentiment": "negative"}, {"name": "immune pharmaceuticals says board will not pursue spin-off of cytovia unit", "sentiment": "negative"}, {"name": "cytovia inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 7 (Reuters) - Immune Pharmaceuticals Inc:\n* IMMUNE PHARMACEUTICALS PROVIDES UPDATE ON PLANS FOR ONCOLOGY SUBSIDIARY, CYTOVIA, INC.\n* IMMUNE PHARMACEUTICALS INC - COMPANY’S BOARD WILL NO LONGER PURSUE A SPIN-OFF OF ITS ONCOLOGY-FOCUSED SUBSIDIARY, CYTOVIA INC\n* IMMUNE PHARMACEUTICALS - DANIEL TEPER HAS RESIGNED AS CEO OF CYTOVIA AND FROM BOARD OF DIRECTORS OF BOTH CYTOVIA AND IMMUNE, EFFECTIVE IMMEDIATELY\n* IMMUNE PHARMACEUTICALS INC - CYTOVIA INC HAD BEEN LED BY IMMUNE’S FOUNDER AND FORMER CHIEF EXECUTIVE OFFICER DANIEL TEPER\n* IMMUNE PHARMACEUTICALS INC - HAS INITIATED DISCUSSIONS WITH PARTIES POTENTIALLY INTERESTED IN ACQUIRING CERTAIN OF CYTOVIA’S ASSETS\n* IMMUNE PHARMACEUTICALS INC - IMMUNE WILL CONTINUE TO FOCUS ITS EFFORTS AND RESOURCES ON DEVELOPMENT OF ITS CORE PROGRAMS, BERTILIMUMAB AND NANOCYCLO Source text for Eikon:\nOur ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-07T20:40:00.000+03:00", "crawled": "2018-05-08T16:38:16.000+03:00", "highlightTitle": ""}